# A Phase 1b/2 Multisite Dose-finding and Expansion Study of WTX-330 in Adult Patients With Selected Advanced or Metastatic Solid Tumors or Lymphoma

Source: https://onco.cc/trials/nct06939283/  
OnCo record `nct06939283` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of WTX-330 in non-Hodgkin lymphoma, run by Werewolf Therapeutics, Inc., active and no longer recruiting.

## Summary

A Phase 1b/2 Multisite Dose-finding and Expansion Study of WTX-330 in Adult Patients With Selected Advanced or Metastatic Solid Tumors or Lymphoma is a phase 1/2 interventional study registered as NCT06939283 by Werewolf Therapeutics, Inc., with 100 participants enrolled, started 2025-05-07 and due to reach its primary completion in 2028-08. Interventions recorded: WTX-330.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06939283
- Phase: 1/2
- Setting: A Phase 1b/2 Multisite Dose- and Regimen-finding and Expansion Study of WTX-330 in Adult Patients With Selected Advanced or Metastatic Solid Tumors or Non-Hodgkin Lymphoma (NHL)
- Sponsor: Werewolf Therapeutics, Inc.
- Enrolled: 100

## Sources

- ClinicalTrials.gov NCT06939283: https://clinicaltrials.gov/study/NCT06939283

## Connected records

- cancers: [Non-Hodgkin lymphoma (all types)](https://onco.cc/cancers/non-hodgkin-lymphoma/)
- companies: [Werewolf Therapeutics](https://onco.cc/companies/werewolf-therapeutics/)

---
JSON: https://onco.cc/api/v1/entities/nct06939283.json